Study of Antiviral Activity of Recombinant Human Interleukin-7 with Various Experimental Models of Hepatitis C Viral Infection

Authors

  • Юлія Іванівна Іванівна Порва SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv, Ukraine
  • Світлана Леонтіївна Рибалко SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv, Ukraine
  • Світлана Терентіївна Дядюн SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv, Ukraine
  • Тетяна Миколаївна Луценко UA “Pro-Pharma” LLC, Kyiv, Ukraine
  • Олександр Юрійович Галкін NTUU KPI, Ukraine https://orcid.org/0000-0002-5309-6099
  • Яніна Олександрівна Похоленко Institute of molecular biology and genetics of NAS of Ukraine, Kyiv, Ukraine
  • Оксана Борисівна Горбатюк Institute of molecular biology and genetics of NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.20535/1810-0546.2015.3.61735

Keywords:

Human interleukin-7 recombinant, Hepatitis C virus, Antiviral activity, Viral load

Abstract

Background. Interleukin-7 (IL-7) is one of the most important regulatory cytokine of immune system. Given the ability of IL-7 to the modulation of T- and B-cell responses and T-cell homeostasis we may assume that IL-7 not only has the ability to influence the formation of specific immunity and immunodeficiency state, but also inhibit the reproduction of viruses, including hepatitis C virus (HCV).

Objective. Study of antiviral activity of recombinant human IL-7 (rIL-7) with experimental models of viral hepatitis C infection in vitro on sensitive virus epithelial and lymphoid cells.

Methods. We have used the following inoculated cell cultures: Jurkat, rat neurinoma of gasserian ganglion and bovine kidney. As used surrogate HCV we used virus of bovine diarrhea. To study the antiviral activity different concentrations of rIL-7 were injected into the cell culture, producing HCV, and determined virus load. Also we have performed cytological analysis of cells and determined its proliferative activity under influence of rIL-7.

Results. It has been shown that rIL-7 inhibits surrogate HCV reproduction in in vitro conditions (SS50 – 3 mg/ml, ED50 – 4.7 ng/ml, IS – 640). Highest proliferation of intact T-cells is determined at rIL-7 doses 0.3 mg/m and 0.025 mg/ml. rIL-7 affected HCV infected cells differently: during the first 3 days the number of cells decreased or did not change, and after 2–3 weeks the number of cells increased almost 2 times. When we injected rIL-7 with dose of 6 mg/ml within 3 days we obtained 89% viral inhibition at the 3rd day and 100 % at the 4th day; using the dose of rIL-7 0.3 mg/ml the inhibition on the 4th day was 100 %; using dose of rIL-7 1.5 mg/ml the inhibition settled at 55 % for 4 days.

Conclusions. As a result of the studies directed towards determining the effect of rIL-7 on surrogate HCV reproduction, HCV cDNA producing transfected human T-cells Jurkat, it was showed that rIL-7 effectively inhibits virus reproduction.

 

Author Biographies

Юлія Іванівна Іванівна Порва, SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv

Yulia I. Porva, Ph.D., senior researcher at the laboratory of experimental chemotherapy of viral infections

Світлана Леонтіївна Рибалко, SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv

Svetlana L. Rybalko, M.D., professor, head of the laboratory of experimental chemotherapy of viral infections

Світлана Терентіївна Дядюн, SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv

Svitlana T. Dyadyun, Ph.D., senior researcher at the laboratory of experimental chemotherapy of viral infections

Тетяна Миколаївна Луценко, UA “Pro-Pharma” LLC, Kyiv

Tatiana N. Lutsenko, head of the R&D group

Олександр Юрійович Галкін, NTUU KPI

Alexander Yu. Galkin, Ph.D., associate professor, assistant professor at the Industrial Biotechnology Department of Faculty of Biotechnology and Biotechnics

Яніна Олександрівна Похоленко, Institute of molecular biology and genetics of NAS of Ukraine, Kyiv

Yanina A. Poholenko, junior researcher at the Department of cell regulatory mechanisms

Оксана Борисівна Горбатюк, Institute of molecular biology and genetics of NAS of Ukraine, Kyiv

Oksana B. Gorbatyuk, Ph.D., researcher at the Department of cell regulatory mechanisms

References

T.J. Fry and C.L. Maskall, “Interleukin-7: from bench to clinic”, Blood, vol. 99, no. 11, pp. 3892–3894, 2002.

E. Bolotin et al., “Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count”, Bone Marrow Transplant., vol. 23, pp. 783–788, 1999.

S.A. Rosenberg et al., “IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells”, J. Immunother., vol. 29, no. 3, pp. 313–319, 2006.

B. De Saint-Vis et al., “The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation”, J. Immunol., vol. 160, no. 4, pp. 1666–1676, 1998.

R.V. Sorg et al., “Human dendritic cells express functional interleukin-7”, Immunobiology, vol. 198, no. 5, pp. 514–526, 1998.

D. Clarke et al., “Interaction of interleukin-7 (IL-7) with glycosaminoglycans and its biological relevance”, Cytokine, vol. 7, no. 4, pp. 325–330, 1995.

K. Kimura et al., “Role of glycosaminoglycans in the regulation of T cell proliferation induced by thymic stroma-derived T cell growth factor”, J. Immunol., vol. 146, no. 8, pp. 2618–2624, 1991.

P. Macchi et al., “Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)”, Nature, vol. 377, no. 6544, pp. 65–68, 1995.

S. Russell et al., “Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development”, Science, vol. 270, no. 5237, pp. 797–800, 1995.

T. Fry and C. Mackall, “Interleukin-7: master regulator of peripheral T-cell homeostasis?”, Trends Immunol., vol. 22, no. 10, pp. 564–571, 2001.

R. Hardy et al., “Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow”, J. Exp. Med., vol. 173, no. 5, pp. 1213–1225, 1991.

P.J. Morrissey et al., “Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation”, J. Immunol., vol. 146, no. 5, pp. 1547–1552, 1991.

D. Lynch et al., “In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes”, Eur. J. Immunol., vol. 21, no. 12, pp. 2977–2985, 1991.

A.W. Plumb et al., “Interleukin-7, but not thymic stromal lymphopoietin, plays a key role in the T cell response to influenza A virus”, PLoS One, vol. 7, no. 11, pp. e50199, 2012.

J. Larrubia et al., “Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation”, Proc. Nat. Acad. Sci. USA, vol. 110, no. 2, pp. 612–617, 2013.

L. Hou et al., “Early IL-7 production by intrahepatic T cell is important for adaptive immune responses in viral hepatitis”, J. Immunol., vol. 190, no. 2, pp. 621–629, 2013.

V.N. Blumkin and V.M. Zhdanov, The Impact of Viruses on the Chromosome Apparatus and Cell Division. Moscow, Russia: Medicina, 1973, 128 p.

Published

2015-07-03